Category Archives: Global News Feed

BRISBANE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the year ended December 31, 2022 and provided a corporate update.

See the original post here:
Tempest Reports Year End 2022 Financial Results and Provides Business Update

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States

See the article here:
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancer Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancer

Go here to see the original:
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward process

The rest is here:
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and olderOral film delivery from SYMPAZAN® delivers clobazam to LGS patients with no crushing, no mixing, no prep work

Go here to see the original:
Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation

Investment will accelerate deployment of the world’s first photosynthesis-enhanced trees and fund additional R&D to develop synthetic biotech solutions to climate change Investment will accelerate deployment of the world’s first photosynthesis-enhanced trees and fund additional R&D to develop synthetic biotech solutions to climate change

Read this article:
Living Carbon raises new funding to plant 4M fast-growing, carbon-guzzling supertrees in US